Drug intelligence / Profile preview

GBV-101

Development stage: Preclinical
Lead developer: CalciMedica
Administration: Ophthalmic

Overview

GBV-101 is a sustained-release implant developed by Graybug Vision for the treatment of glaucoma. As of around 2018, the drug was in the preclinical/seed stage, with preparations underway for an Investigational New Drug (IND) submission.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR-1 (Vascular endothelial growth factor receptor 1)

Beyond the preview

Go deeper on GBV-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GBV-101.

Explore the full profile